by SaNOtize Research hopes to prevent it from incubating and spreading to the lungs. This basic nasal spray uses nitric oxide (NO), a natural nano-molecule with antimicrobial characteristics that has a direct effect on SARS-CoV-2. According to the clinical trials of SaNOtize for the drug in the UK and Canada, NONS anti-COVID nasal spray lowered average viral occupancy by about 95% in the first 24 hours and by over 99 percent in the first 72 hours.
Glenn Saldanha, Chairperson and MD of Glenmark Pharmaceuticals commented on the new partnership between Glenmark and SaNotize. He said, “It also marks another valuable in-licensing opportunity for us in our key therapy area of respiratory medicine, as well as the possibility to globally supply the product to SaNOtize and its partners outside of our territory. Glenmark will ensure timely and widespread access to this effective nasal spray, which we hope will bring much needed relief to patients across the region and the wider world”.
Dr Gilly Regev, CEO and co-founder of SaNOtize expressed delight over the partnership. He said, “SaNotize is excited to collaborate with Glenmark in providing broader, easier and affordable access to its treatment. In joining forces with Glenmark, SaNotize can accelerate the efforts to have its antiviral nasal spray available as a self-administered, first line of defence against COVID-19 during the current pandemic and to help prevent future outbreaks”.
